DSGN vs. CTNM, PYXS, IMMP, TSVT, NKTR, ENTA, CTMX, XERS, XBIT, and RAPT
Should you be buying Design Therapeutics stock or one of its competitors? The main competitors of Design Therapeutics include Contineum Therapeutics (CTNM), Pyxis Oncology (PYXS), Immutep (IMMP), 2seventy bio (TSVT), Nektar Therapeutics (NKTR), Enanta Pharmaceuticals (ENTA), CytomX Therapeutics (CTMX), Xeris Biopharma (XERS), XBiotech (XBIT), and RAPT Therapeutics (RAPT). These companies are all part of the "pharmaceutical preparations" industry.
Contineum Therapeutics (NASDAQ:CTNM) and Design Therapeutics (NASDAQ:DSGN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk.
In the previous week, Contineum Therapeutics and Contineum Therapeutics both had 2 articles in the media. Contineum Therapeutics' average media sentiment score of 1.09 beat Design Therapeutics' score of -1.50 indicating that Design Therapeutics is being referred to more favorably in the news media.
Design Therapeutics received 7 more outperform votes than Contineum Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Contineum Therapeutics an outperform vote while only 34.48% of users gave Design Therapeutics an outperform vote.
Design Therapeutics' return on equity of 0.00% beat Contineum Therapeutics' return on equity.
Contineum Therapeutics presently has a consensus price target of $28.00, suggesting a potential upside of 78.23%. Design Therapeutics has a consensus price target of $6.60, suggesting a potential upside of 46.99%. Given Design Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Contineum Therapeutics is more favorable than Design Therapeutics.
56.6% of Design Therapeutics shares are owned by institutional investors. 25.7% of Design Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Contineum Therapeutics beats Design Therapeutics on 6 of the 10 factors compared between the two stocks.
Get Design Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for DSGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DSGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Design Therapeutics Competitors List
Related Companies and Tools
